Cargando…

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

BACKGROUND: Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK(+) NSCLC) is a model disease for use of targeted therapies (TKI), which are administered sequentially to maximize patient survival. METHODS: We retrospectively analyzed the flow of 145 consecutive TKI-treated ALK(+) NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elsayed, Mei, Bozorgmehr, Farastuk, Kazdal, Daniel, Volckmar, Anna-Lena, Sültmann, Holger, Fischer, Jürgen R., Kriegsmann, Mark, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096170/ https://www.ncbi.nlm.nih.gov/pubmed/33959513 http://dx.doi.org/10.3389/fonc.2021.670483

Ejemplares similares

Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
por: Christopoulos, Petros, et al.
Publicado: (2021)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma
por: Fisch, David, et al.
Publicado: (2021)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report
por: Wiedemann, Christiane, et al.
Publicado: (2022)

Defining molecular risk in ALK(+) NSCLC
por: Christopoulos, Petros, et al.
Publicado: (2019)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report
por: Volckmar, Anna-Lena, et al.
Publicado: (2016)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
por: Angeles, Arlou Kristina, et al.
Publicado: (2021)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
por: Angeles, Arlou Kristina, et al.
Publicado: (2023)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
por: Schindler, Hannah, et al.
Publicado: (2022)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival
por: Christopoulos, Petros, et al.
Publicado: (2019)

Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
por: Janke, Florian, et al.
Publicado: (2022)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report
por: Ou, Kai, et al.
Publicado: (2021)

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
por: Gao, Peng, et al.
Publicado: (2022)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
por: Hohmann, Nicolas, et al.
Publicado: (2020)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
por: Eichkorn, Tanja, et al.
Publicado: (2020)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review
por: Huimin, Zhou, et al.
Publicado: (2022)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
por: Feng, Chunlai, et al.
Publicado: (2021)

High-risk patients with locally advanced non-small cell lung cancer treated with stereotactic body radiation therapy to the peripheral primary combined with conventionally fractionated volumetric arc therapy to the mediastinal lymph nodes
por: Eichkorn, Tanja, et al.
Publicado: (2023)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2020)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
por: Bozorgmehr, Farastuk, et al.
Publicado: (2023)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
por: Wang, Zhan, et al.
Publicado: (2022)

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review
por: Chen, Qin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pu91f9e2tgabbfbhia5pobu931